Migration of mesenchymal stem cells to heart allografts during chronic rejection

Wu, Guey-Shuang; Nolta, Jan A.; Jin, Yang-Sun; Barr, Mark L.; Yu, Hong; Starnes, Vaughn A.; Cramer, Donald V.

doi:10.1097/01.tp.0000048488.35010.95

Cited by 167 publications

(126 citation statements)

References 24 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Successful systemic delivery of MSC is dependent upon efficient homing of the cells to the required site. In this respect, the migration of MSC from the circulation into damaged or pathological tissues leading to therapeutic effects has been documented (Chen et al, 2001;Horwitz et al, 2002;Ortiz et al, 2003;Wu et al, 2003). More importantly, these studies documented the absence of non-specific trafficking of MSC to undamaged tissue, i.e.…”

Section: Methods Of Therapeutic Administration Of Mscmentioning

confidence: 88%

“…Wang et al (2006), on the other hand, reported a reduction in the circulating pool of MSC in patients 1-week after MI and suggested that the MSC may have been recruited to the damaged myocardium. There are also several reports of the derivation of MSC from circulating fetal blood or umbilical cord (Ye et al, 1994;Campagnoli et al, 2000Campagnoli et al, , 2001Erices et al, 2000), and of the presence of MSC in the peripheral blood of other species (Huss et al, 2000;Wu et al, 2003). The two studies by Mansilla et al (2006) and Wang et al (2006) suggest that injury/trauma might evoke the release of MSC; thus systemic administration of MSC might enhance the presence of the circulating MSC, which may ultimately lead to an enhanced therapeutic response if the cells can be efficiently targeted to the damaged tissues.…”

Section: Do Msc Occur Naturally In the Blood?mentioning

confidence: 99%

See 1 more Smart Citation

Recent advances into the understanding of mesenchymal stem cell trafficking

et al. 2007

View full text Add to dashboard Cite

SummaryThe use of adult stem cells to regenerate damaged tissue circumvents the moral and technical issues associated with the use of those from an embryonic source. Mesenchymal stem cells (MSC) can be isolated from a variety of tissues, most commonly from the bone marrow, and, although they represent a very small percentage of these cells, are easily expandable. Recently, the use of MSC has provided clinical benefit to patients with osteogenesis imperfecta, graft-versushost disease and myocardial infarction. The cellular cues that enabled the MSC to be directed to the sites of tissue damage and the mechanisms by which MSC then exert their therapeutic effect are becoming clearer. This review discusses the relative therapeutic importance of the ability of MSC to differentiate into multiple cell lineages or stimulate resident or attracted cells via a paracrine mode of action. It also reviews recent findings that MSC home to damaged tissues in a similar, but somewhat distinct, manner to that of leucocytes via the utilisation of adhesion molecules, such as selectins and integrins, and chemokines and their receptors in a manner reminiscent of leucocytes trafficking from the blood stream to inflammatory sites.

show abstract

Section: Methods Of Therapeutic Administration Of Mscmentioning

confidence: 88%

Section: Do Msc Occur Naturally In the Blood?mentioning

confidence: 99%

Recent advances into the understanding of mesenchymal stem cell trafficking

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In most forms of chronic vascular damage and repair, MSC home to and accumulate at sites where other cell types are actively dying [24,25,[52][53][54]. In chronic rejection, T-cell-dependent and antibody responses target the endothelium, contributing to a sustained increase in endothelial apoptosis [6][7][8][9][10][11][12]55].…”

Section: Discussionmentioning

confidence: 99%

Epidermal Growth Factor and Perlecan Fragments Produced by Apoptotic Endothelial Cells Co-Ordinately Activate ERK1/2-Dependent Antiapoptotic Pathways in Mesenchymal Stem Cells

et al. 2010

View full text Add to dashboard Cite

Mounting evidence indicates that mesenchymal stem cells (MSC) are pivotal to vascular repair and neointima formation in various forms of vascular disease. Yet, the mechanisms that allow MSC to resist apoptosis at sites where other cell types, such as endothelial cells (EC), are dying are not well defined. In the present work, we demonstrate that apoptotic EC actively release paracrine mediators which, in turn, inhibit apoptosis of MSC. Serum-free medium conditioned by apoptotic EC increases extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation and inhibits apoptosis (evaluated by Bcl-xL protein levels and poly (ADP-ribose) polymerase cleavage) of human MSC. A C-terminal fragment of perlecan (LG3) released by apoptotic EC is one of the mediators activating this antiapoptotic response in MSC.LG3 interacts with b1-integrins, which triggers downstream ERK1/2 activation in MSC, albeit to a lesser degree than medium conditioned by apoptotic EC. Hence, other mediators released by apoptotic EC are probably required for induction of the full antiapoptotic phenotype in MSC. Adopting a comparative proteomic strategy, we identified epidermal growth factor (EGF) as a novel mediator of the paracrine component of the endothelial apoptotic program.LG3 and EGF cooperate in triggering b1-integrin and EGF receptor-dependent antiapoptotic signals in MSC centering on ERK1/2 activation. The present work, providing novel insights into the mechanisms facilitating the survival of MSC in a hostile environment, identifies EGF and LG3 released by apoptotic EC as central antiapoptotic mediators involved in this paracrine response. STEM CELLS 2010;28:810-820 Disclosure of potential conflicts of interest is found at the end of this article.

show abstract

“…It has been discovered in allograft studies conducted with rats that MSCs immigrate to the area of rejection and settle there after infusion [16]. MSCs are found to have improved the intestinal damage in studies concerning inflammatory bowel disease [17].…”

Section: Discussionmentioning

confidence: 99%

Transplantation of Single Mismatch Hematopoietic Stem Cells with Third Party Mesenchymal Stem Cells for Severe Aplastic Anemia: A Case Report and Mini Review

Keni¹

2017

Ann Hematol Oncol

View full text Add to dashboard Cite

While allogeneic hematopoietic stem cells transplantation (allo-HSCT)from HLA-identical siblings has high success rates for aplastic anemia, transplantation from HLA identical or mismatched unrelated donors carries a higher risk of engraftment failure and graft versus host disease (GVHD), remarkably reducing its success rate. A 36 year old woman was diagnosed with severe aplastic anemia and paroxysmal nocturnal hemoglobinuria. Immunosuppressive therapy failed and there was no available HLA compatible family donor. Allo-HSCT was performed using a 9/10 matched unrelated donor with the support of third party mesenchymal stem cells. On patient follow-up, successful engraftment was obtained and neither acute nor chronic graft-versus-host-disease was observed. Mesenchymal stem cells which have immunomodulatory, migratory and regenerative properties may increase the changes of success in unrelated HSCT.

show abstract

Migration of mesenchymal stem cells to heart allografts during chronic rejection

Cited by 167 publications

References 24 publications

Recent advances into the understanding of mesenchymal stem cell trafficking

Recent advances into the understanding of mesenchymal stem cell trafficking

Epidermal Growth Factor and Perlecan Fragments Produced by Apoptotic Endothelial Cells Co-Ordinately Activate ERK1/2-Dependent Antiapoptotic Pathways in Mesenchymal Stem Cells

Transplantation of Single Mismatch Hematopoietic Stem Cells with Third Party Mesenchymal Stem Cells for Severe Aplastic Anemia: A Case Report and Mini Review

Contact Info

Product

Resources

About